Live Breaking News & Updates on ய்வ் மீண்டும் பயன்படுத்தவும்

Message :
Required fields
AFM24 preclinical in vivo data will be presented as a poster
Data on AFM13 in combination with adoptive NK cells will be presented
during a Major Symposium
Heidelberg, Germany, March 10, 2021 Affimed N.V. (Nasdaq: AFMD), a
clinical-stage immuno-oncology company committed to giving patients back
their innate ability to fight cancer, announced today that preclinical
anti-tumor efficacy in vivo data from its innate cell engager (ICE(R) )
AFM24 have been accepted for e-poster presentation at the American
Association for Cancer Research (AACR) Virtual Annual Meeting I, being
held on April 10-15.
In addition, early data from a Phase 1 study evaluating AFM13 preloaded ....

United States , New York , Baden Wuberg , Cassandra Choe Juliak , Affimednv Affimed , Gabriele Hintzen , Jens Pahl , Sheena Pinto , Torsten Haneke , Uwe Reusch , Andreas Harstrick , Katy Rezvani , Joachim Koch , Arndt Schottelius , Mary Beth Sandin , Christian Breunig , Wolfgang Fischer , Panel Session , American Association For Cancer Research , University Of Texas Md Anderson Cancer Center , Md Anderson Cancer Center , Department Of Stem Cell Transplantation , Cancer Research Professor Of Medicine , Translational Research , Major Symposium , Cancer Research ,